Group 1: Modern Industrial System Development - The core focus is on establishing a modern industrial system to support high-quality development, emphasizing advanced manufacturing as the backbone [1] - The strategy includes upgrading traditional industries towards high-end, intelligent, and green transformations during the "14th Five-Year Plan" period [1] - Key projects include enhancing the high-end chemical industry, food processing, and sports equipment manufacturing to create competitive industrial clusters [1] Group 2: Emerging Industry Cultivation - The plan aims to promote the scale and cluster development of emerging industries during the "14th Five-Year Plan" period [2] - Significant projects include the comprehensive layout of semiconductor industries and the establishment of national-level innovation platforms in the information technology sector [2] - The biopharmaceutical industry is targeted for growth, with support for major companies to create national strategic emerging industry clusters [2] Group 3: Future Industry Layout - A mechanism for increasing investment in future industries will be established, focusing on incubators and acceleration parks [3] - The hydrogen energy industry is highlighted, with plans to create a comprehensive industrial chain for fuel cells and related systems [3] - The artificial intelligence sector will see integration with various industries, supported by the development of AI equipment industrial parks and data centers [3]

Core Insights - The article discusses Shenzhen's new action plan aimed at leveraging the insurance industry to support technological innovation and industrial development from 2026 to 2028 [1][11]. Group 1: Action Plan Overview - The action plan outlines sixteen measures to enhance insurance support for technology innovation and industrial development, with specific responsibilities assigned to various units [3][4]. - The plan aims to establish a modern insurance service system aligned with Shenzhen's economic development, supporting strategic emerging industries and enhancing financial cooperation with Hong Kong [4][12]. Group 2: Goals and Targets - By the end of 2028, the plan targets an annual risk coverage of over 5 trillion yuan for technology enterprises, with an average annual growth rate of over 10% in technology insurance premium income [4][12]. - The total assets of insurance entities in Shenzhen are expected to exceed 11 trillion yuan, with total premium income surpassing 700 billion yuan over three years [5][13]. Group 3: Specific Measures - The plan includes optimizing insurance fund utilization, promoting technology insurance, and enhancing support for the "20+8" strategic emerging industry clusters [6][14]. - It encourages insurance institutions to invest over 1 trillion yuan in Shenzhen, focusing on key sectors such as artificial intelligence, biotechnology, and low-altitude economy [6][7]. Group 4: Collaboration and Innovation - The action plan emphasizes collaboration between the insurance industry and various sectors, including the establishment of insurance innovation centers and the development of tailored insurance products for emerging technologies [8][15]. - It also highlights the importance of enhancing the insurance service system for the marine industry and promoting cross-border insurance cooperation with Hong Kong [17][19]. Group 5: Support and Coordination - The plan outlines measures to strengthen organizational coordination and promote public awareness of insurance policies and products [21][22]. - It aims to facilitate the integration of insurance services with industrial needs, enhancing the efficiency and effectiveness of insurance offerings [21][22].

Summary of China Healthcare Industry Conference Call Industry Overview - **Industry**: China Healthcare Industry - **Report Date**: January 21, 2026 - **Sentiment**: Cautiously optimistic outlook for 2026 regarding hospital capital expenditures and market dynamics [1][2] Key Insights Capital Expenditure Trends - **Stable to Moderate Growth**: Hospital capital expenditures are expected to remain stable with moderate growth in 2026 [2] - **Survey Results**: 59% of surveyed hospital managers anticipate capital expenditure growth in 2026, up from 43% in late 2024, but still below 85% in late 2023 [3] - **Projected Growth Rate**: Expected capital expenditure growth of 4.7% in 2026, compared to 3.0% growth anticipated for 2025 [3] - **Actual Growth Expectations**: Respondents expect actual capital expenditure growth of 5.8% for 2025, indicating limited visibility on actual demand [3] Key Drivers of Expenditure - **Primary Drivers**: 1. Hospital Surplus (69%) 2. Patient Demand (50%) 3. Local Fiscal Budgets (44%) [3] - **Service Volume Constraints**: Factors such as Diagnosis-Related Group (DRG) payment limits and medical insurance settlements are seen as major constraints on service volume [3] Equipment and Technology Focus - **Investment Priorities**: Hospitals are prioritizing investments in AI, endoscopy, and imaging equipment, with a focus on surgical and flexible endoscopes, followed by CT and ultrasound [3] - **Weak Demand**: In vitro diagnostics are expected to remain weak [3] Company-Specific Insights Beneficiaries of Capital Expenditure Growth - **Mindray Medical (300760.SZ)**: Expected to benefit from a stable capital expenditure environment, with anticipated single-digit revenue growth in 2026. The company is expected to maintain a 16% share of planned capital expenditures [4][10] - **United Imaging (688271.SS)**: Anticipated to benefit from strong demand in high-end imaging, with projected revenue growth of approximately 21% in 2026 [4][11] - **New Industries (300832.SZ)**: Expected to face continued pricing pressure in in vitro diagnostics but may achieve above-industry growth due to healthy demand for chemical luminescence analyzers [4][12] - **Huatai Medical (688617.SS)**: Positioned to capitalize on the growing adoption of pulse field ablation technology, with projected revenue growth of 30% in 2026 [4][13] - **Guichuang Tongqiao (2190.HK)**: Expected to see revenue growth of around 30% driven by increased demand for neurointerventional and peripheral interventional procedures [4][15] Challenges for Global Players - **GE Healthcare**: Faces mixed impacts from increased capital expenditure and growing preference for local brands, which may offset some growth [4][16] - **Siemens Healthineers (SHL)**: Cautious outlook due to slow recovery in utilization rates and increased pricing pressure from procurement policies [4][17] - **Philips (PHIA)**: Similar cautious outlook with potential declines in market share for CT and ultrasound equipment [4][18] - **Olympus (7733.T)**: Expected to face challenges in maintaining market share in the digestive endoscopy market [4][19] - **Hologic (6869.T)**: Anticipated slowdown in clinical testing volumes and potential market share decline in hematology [4][20] Additional Observations - **Market Dynamics**: The report highlights a complex landscape for global medical technology companies in China, with both opportunities and pressures from local competition and procurement policies [4][16][17][18][19][20] - **Emerging Trends**: The shift towards local brands and the impact of procurement policies are significant trends that may reshape the competitive landscape in the healthcare sector [4][16][17][18][19][20]

数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评估和预测仅反映当前的判 ...

Core Viewpoint - Jiangxi Ruijin City is focusing on developing three manufacturing clusters: precision manufacturing, cultural and creative toys, and textile and apparel, aiming for a chain-based and clustered development of key industries [2][4][6][7] Group 1: Manufacturing Development - Ruijin City plans to add 21 new industrial enterprises above designated size by 2025, bringing the total to 145 [2][4][6][7] - The industrial added value above designated size in Ruijin City is expected to grow by 12.8% year-on-year [2][4][6][7] Group 2: Industry Focus - The three key manufacturing clusters being developed are precision manufacturing, cultural and creative toys, and textile and apparel [2][4][6][7] - The emphasis on these clusters indicates a strategic move towards enhancing local manufacturing capabilities and economic growth [2][4][6][7]

Group 1 - The core viewpoint of the news is the introduction of eight supportive policies aimed at enhancing enterprise development in Jiangsu Province, combining both existing and new financial support measures [1][2][3] - The manufacturing loan interest subsidy policy has been optimized and expanded, allowing two types of enterprises to directly benefit from interest subsidies, specifically "C manufacturing" enterprises and recognized "little giant" enterprises [1] - The modern service industry loan interest subsidy policy has seen improvements, with a budget of 150 million yuan for 2026, increasing the subsidy rate from 1% to 1.5%, and expanding the eligible sectors to include various service industries [2] Group 2 - Jiangsu has implemented a "fiscal + financial" strategy to address enterprise financing challenges, resulting in significant financial support for sectors such as technology innovation and advanced manufacturing [3] - The province has introduced a comprehensive framework of 20 measures and over 60 policy points to support high-quality economic development, with 4.6 billion yuan allocated for fiscal subsidies [3] - The policies aim to leverage financial resources, with over 600 billion yuan mobilized to support various sectors, including small and micro enterprises [3]

Core Viewpoint - Yantai's "14th Five-Year Plan" aims to establish a new development blueprint, with a focus on high-quality growth and positioning Yantai as a leading city in the region [1] Group 1: Development Goals and Strategies - The "14th Five-Year Plan" outlines one main goal and six key positions for Lai Zhou, aiming to become a leader in county-level economic development and rejoin Yantai's top tier [2] - The six key positions include being a western gateway to national strategies, a demonstration zone for green energy transition, a hub for new chemical materials, a base for specialized machinery manufacturing, a leading green gold production area, and a high ground for marine economy in the Bohai Sea [2] Group 2: Industrial Transformation and Upgrading - Lai Zhou focuses on integrating traditional and emerging industries, particularly in new energy and chemical materials, with a target of achieving a total industrial output value of over 200 billion yuan by 2030 for both sectors [3] - The gold industry aims to develop a thousand-billion-level industrial cluster by 2030, with a projected output value of 1,200 billion yuan, while the stone industry targets an output value of over 100 billion yuan [3] Group 3: Strengthening Key Industries - The mechanical manufacturing sector is encouraged to innovate towards new energy, automation, and intelligence, aiming for an output value of over 150 billion yuan by 2030 [4] - The automotive parts industry is focusing on the smart and connected vehicle trend, also targeting an output value of over 150 billion yuan by 2030 [4] - The cultural tourism sector aims to attract 8 million visitors annually and generate over 100 billion yuan in tourism revenue by 2030 [4] Group 4: Economic Growth Drivers - Lai Zhou plans to invest over 230 billion yuan in 2026, with a focus on 96 key projects totaling 1,106.2 billion yuan, ensuring a construction project commencement rate of over 50% in Q1 and 70% in H1 [5][6] - The strategy includes stimulating consumption through various promotional activities and supporting the real estate market to stabilize and grow [6] Group 5: Regional Coordination and Urban-Rural Development - The city aims to enhance urban quality and manage resources effectively, focusing on urban renewal and infrastructure improvements [7] - Rural revitalization efforts will include creating model areas and integrating agricultural, cultural, and tourism projects to enhance rural living standards and economic viability [7]

Core Viewpoint - The city of Jinan, particularly the Shizhong District, is focused on advancing its economic development and industrial transformation through strategic initiatives and projects aimed at enhancing productivity and quality of life in the region [1][3]. Economic Development - The Shizhong District's GDP is expected to exceed 140 billion yuan, indicating a positive economic trajectory supported by significant projects like the Hong Kong Yuhu Cold Chain [3]. - The district aims to stabilize employment, businesses, and market expectations, contributing to a steady economic growth [3]. Financial Sector Development - The district plans to leverage its financial headquarters' advantages by promoting a "technology-industry-finance" service system, enhancing the collaboration between traditional and new financial sectors [6]. - Initiatives include establishing government investment funds and market-oriented industry funds to support strategic investments in sectors like artificial intelligence and new energy equipment [6]. Industrial Transformation - The district is focusing on the integration of energy resources and aims to develop a robust energy internet industry cluster, emphasizing new power equipment and artificial intelligence in the power sector [7]. - There is a commitment to advancing urban industrialization by fostering new industries such as artificial intelligence and new energy vehicles, alongside the development of significant projects like the Yuhu Cold Chain [9]. Cultural and Creative Industries - The district is promoting a dual approach to cultural development by enhancing both cultural enterprises and cultural services, with a focus on digital transformation and the growth of new cultural industries [10]. - Plans include upgrading historical cultural districts and fostering more cultural tourism projects to enhance the region's cultural influence [10]. Public Services and Social Governance - The district aims to improve public services in education, healthcare, and community governance, ensuring that resources are equitably distributed between urban and rural areas [12]. - There is a focus on integrating urban and rural development to create a cohesive and supportive environment for the district's "second entrepreneurship" mission [12].

证券之星消息，1月21日，生物经济（970038）指数报收于2249.37点，涨0.3%，成交272.77亿元，换手 率2.27%。当日该指数成份股中，上涨的有28家，迪安诊断以5.59%的涨幅领涨，下跌的有22家，康弘药 业以1.78%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000021 | 深科技 | 1.87亿 ﮯ | 3.06% | -9441.13万 | -1.55% | -9272.83万 | -1.52% | | 300142 | 沃森生物 | 6444.78万 | 8.62% | -3115.26万 | -4.16% | -3329.52万 | -4.45% | | 000930 | 中粮科技 | 5427.62万 | 9.84% | 491.65万 | 4 0.89% | -5919.27万 | -10.73% | | 002 ...

Group 1 - The core viewpoint of the news highlights the positive performance of the medical device sector, with significant stock price increases for various companies and a favorable market outlook driven by new pricing policies and international trade initiatives [1][2][3] Group 2 - As of January 21, the Shanghai Composite Index rose by 0.22%, while the medical device index increased by 0.69%, with notable stock performances from Tianzhihang-U (+13%), Sanyou Medical (+7%), and others [1] - The medical device ETF (562600) saw a 0.77% increase, with a trading volume of 254.268 billion yuan and a turnover rate of 4.15%. Over the past six months, the fund has gained 4.80%, and 11.30% over the past year [1] Group 3 - On January 20, the National Healthcare Security Administration issued guidelines for pricing medical services related to surgical robots and remote surgeries, establishing a structured pricing system to enhance innovation returns and improve accessibility to precision medicine [2] - A special seminar was held on January 17 to discuss how to leverage the medical device procurement and pricing platform to support the international expansion of Chinese medical devices, with plans for a cross-border channel based on procurement platforms in Guangxi and Tianjin [2] Group 4 - Multiple authoritative institutions have expressed optimism about the medical device sector, with expectations for a turning point in operations by 2026 due to optimized procurement rules and significant growth potential in domestic and international markets for surgical robots and AI medical technologies [3] - The medical device ETF (562600) tracks the CSI All Index for medical devices, with the top ten weighted stocks accounting for 45.04% of the total, including major players like Mindray Medical and United Imaging [3]